Segment Information (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
|
Mar. 31, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
segment
|
Sep. 30, 2025
USD ($)
|
|
| Segment Information | ||||||||
| Number of reportable segment | segment | 1 | |||||||
| Revenue | $ 10,000 | $ 11,000 | $ 10,000 | |||||
| Research and development expenses | 58,474 | $ 34,402 | 181,826 | 112,343 | ||||
| General and administrative | 27,435 | 13,178 | 60,092 | 37,730 | ||||
| Stock-based compensation | 17,276 | 7,336 | 35,090 | 18,767 | ||||
| Net loss | (108,923) | $ (111,456) | $ (80,987) | (51,499) | $ (52,223) | $ (33,573) | (301,366) | (137,295) |
| Zenas Inc | ||||||||
| Segment Information | ||||||||
| Revenue | 10,000 | |||||||
| Zenas BioPharma (HK) Limited | ||||||||
| Segment Information | ||||||||
| Revenue | 0 | 1,000 | 10,000 | |||||
| Single Reportable Segment | ||||||||
| Segment Information | ||||||||
| Revenue | 10,000 | 11,000 | 10,000 | |||||
| General and administrative | 14,427 | 8,245 | 36,227 | 25,060 | ||||
| Acquired in-process research and development | 27,500 | 5,000 | 57,500 | 5,000 | ||||
| Stock-based compensation | 17,276 | 7,336 | 35,090 | 18,767 | ||||
| Other segment items | 5,514 | (1,081) | 12,948 | (7,778) | ||||
| Net loss | $ (108,923) | $ (51,499) | $ (301,366) | $ (137,295) | ||||
| Other segment items, description | Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior notes as well as realized and unrealized gains and losses on foreign currency transactions | Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior notes as well as realized and unrealized gains and losses on foreign currency transactions | Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior notes as well as realized and unrealized gains and losses on foreign currency transactions | Other segment items consist of other (income) expense, net, and income tax (benefit) provision. Other (income) expense, net consists of interest income, interest expense related to the royalty obligation, the senior secured term loan and convertible senior notes as well as realized and unrealized gains and losses on foreign currency transactions | ||||
| Single Reportable Segment | Obexelimab | ||||||||
| Segment Information | ||||||||
| Research and development expenses | $ 22,589 | $ 20,753 | $ 83,743 | $ 74,006 | ||||
| Single Reportable Segment | Orelabrutinib | ||||||||
| Segment Information | ||||||||
| Research and development expenses | 12,904 | 34,211 | ||||||
| Single Reportable Segment | Other programs (ZB002, ZB004, ZB014, ZB021 & ZB022) | ||||||||
| Segment Information | ||||||||
| Research and development expenses | 2,037 | 467 | 4,063 | 1,204 | ||||
| Single Reportable Segment | Partnered regional programs (ZB001 & ZB005) | ||||||||
| Segment Information | ||||||||
| Research and development expenses | 172 | (24) | 134 | |||||
| Single Reportable Segment | Unallocated | ||||||||
| Segment Information | ||||||||
| Research and development expenses | $ 16,676 | $ 10,607 | $ 48,608 | $ 30,902 | ||||
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of research and development expense incurred during the period related to asset acquired in transaction other than business combination or from joint venture formation or both. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|